share_log

Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $49

Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $49

古根海姆维持对Tarsus Pharmicals的买入,将目标股价上调至49美元
Benzinga ·  2023/09/11 09:52

Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $46 to $49.

古根海姆分析师埃迪·希克曼维持塔尔苏斯制药(纳斯达克:TARS)的买入,并将目标价从46美元上调至49美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发